OptimizeRx

OPRX · NASDAQ

$8.93+$0.19 (+2.17%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $8.74

OPRX analyst rating

BuyConsensus of 7 analysts over the last 12 months. 86% rate it a buy.

Strong buy0
Buy6
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $12.85 (+43.9% upside)

Low: $11.11
Now: $8.93
High: $18.90

Upgrades and downgrades

The latest rating actions, newest first

OPRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B. Riley Securities	Sep 29, 2026	Maintains	Buy	$10.00 → $11.00	44%
Citizens	Aug 14, 2026	Maintains	Market Outperform	$9.00 → $11.00	38%
Lake Street	May 13, 2026	Maintains	Buy	$20.00 → $11.00	48%
B. Riley Securities	May 13, 2026	Maintains	Buy	$11.00 → $10.00	53%
Stephens & Co.	May 13, 2026	Maintains	Equal-Weight	$10.00 → $7.00	34%
Stifel	May 13, 2026	Maintains	Buy	$17.00 → $14.00	55%
Lake Street	Mar 6, 2026	Maintains	Buy	$24.00 → $20.00	48%
Roth Capital	Mar 6, 2026	Maintains	Buy	$32.00 → $18.00	37%
B. Riley Securities	Mar 6, 2026	Maintains	Buy	$28.00 → $11.00	53%
Stephens & Co.	Mar 6, 2026	Maintains	Equal-Weight	$17.00 → $10.00	34%

The case for and against

Updated Oct 15, 2026

Bull case

OptimizeRx is attractive because its core point-of-care network reaches more than 2M HCPs and 240M patients, while DAAP and Micro-Neighborhood Targeting deepen differentiation and support higher-margin, AI-driven monetization. Even after revenue guidance was cut to $95M-$100M and 2Q26 revenue fell 30% Y/Y to $20.5M, EBITDA margin expanded to 24.1% and EBITDA guidance stayed at $21M-$25M, showing strong cost discipline and operating leverage as the mix shifts away from lower-margin managed services. The balance sheet also improved materially after the May 2026 refinance into a $35M facility at about 6.5%, net cash turned positive at $5.1M, and DeepIntent’s May 2026 EHR integration and expected 4Q revenue ramp add a second growth engine.

Bear case

OptimizeRx is facing a deteriorating fundamental setup because 2Q26 revenue fell to $20.5M, down 30% Y/Y, after the loss of a low-margin managed-service stream and a zero-revenue customer, while net revenue retention dropped below 100% for the first time in 2Q26 as large accounts optimized spend. The company remains highly exposed to concentration risk, with roughly 62% of 2025 revenue tied to just two eRx/EHR channel partners and 54% of TTM revenue coming from top 20 pharma manufacturers, leaving execution, partner bargaining power, and customer churn as persistent threats. Although gross margin improved to 76.5% and EBITDA margin expanded to 24.1%, the 2026 outlook still depends on a steep 4Q ramp to 35%–40% of annual sales amid MFN, IRA, and broader pharma budget uncertainty.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.